Hikari Power Ltd Purchases 1,130 Shares of Merck & Co., Inc. (NYSE:MRK)

Hikari Power Ltd raised its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 5.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,630 shares of the company’s stock after purchasing an additional 1,130 shares during the quarter. Hikari Power Ltd’s holdings in Merck & Co., Inc. were worth $1,939,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Sheets Smith Wealth Management increased its holdings in Merck & Co., Inc. by 0.5% in the 4th quarter. Sheets Smith Wealth Management now owns 24,741 shares of the company’s stock valued at $1,896,000 after purchasing an additional 124 shares during the last quarter. Ritter Daniher Financial Advisory LLC lifted its position in shares of Merck & Co., Inc. by 33.9% during the 4th quarter. Ritter Daniher Financial Advisory LLC now owns 517 shares of the company’s stock worth $40,000 after purchasing an additional 131 shares during the last quarter. First Interstate Bank lifted its position in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. First Interstate Bank now owns 8,509 shares of the company’s stock worth $653,000 after purchasing an additional 134 shares during the last quarter. Mckinley Capital Management LLC Delaware lifted its position in Merck & Co., Inc. by 0.9% in the fourth quarter. Mckinley Capital Management LLC Delaware now owns 14,621 shares of the company’s stock valued at $1,121,000 after acquiring an additional 135 shares during the last quarter. Finally, Capital City Trust Co. FL lifted its position in Merck & Co., Inc. by 4.2% in the fourth quarter. Capital City Trust Co. FL now owns 3,376 shares of the company’s stock valued at $259,000 after acquiring an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 72.88% of the company’s stock.

NYSE MRK opened at $89.16 on Thursday. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $94.92. The stock’s 50-day moving average is $88.75 and its two-hundred day moving average is $82.17. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.40 and a quick ratio of 1.14. The firm has a market cap of $225.47 billion, a P/E ratio of 15.95, a price-to-earnings-growth ratio of 1.19 and a beta of 0.36.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.81 by $0.33. Merck & Co., Inc. had a return on equity of 47.86% and a net margin of 26.27%. The company had revenue of $15.90 billion for the quarter, compared to the consensus estimate of $14.64 billion. During the same period last year, the business posted $1.40 earnings per share. The firm’s revenue was up 31.6% compared to the same quarter last year. On average, equities analysts expect that Merck & Co., Inc. will post 7.32 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 8th. Shareholders of record on Wednesday, June 15th will be issued a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date of this dividend is Tuesday, June 14th. Merck & Co., Inc.’s payout ratio is 49.37%.

A number of research analysts have commented on MRK shares. Mizuho started coverage on shares of Merck & Co., Inc. in a research note on Friday, April 1st. They issued a “buy” rating and a $100.00 price objective on the stock. StockNews.com initiated coverage on Merck & Co., Inc. in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. Morgan Stanley decreased their target price on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. Barclays boosted their price target on Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a report on Tuesday, April 12th. Finally, SVB Leerink reissued an “outperform” rating and issued a $102.00 price target on shares of Merck & Co., Inc. in a report on Monday, June 6th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $91.60.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.